Olanzapine Market by Application (Bipolar Disorder, Others and Schizophrenia), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC, and RoW) - Forecast to 2027
Olanzapine is an oral tablet used in the treatment of depression, schizophrenia and bipolar I disorder. It is available as an orally disintegrating tablet which dissolves quickly in the mouth and a tablet. The side effects related to olanzapine are difficulty in swallowing, dizziness, headache, feeling tired or restless, and drowsiness. Olanzapine is also used along with fluoxetine for the treatment of depression in adults and children at least 10 years old who have bipolar I disorder. Expansion of the olanzapine market size is propelled by surge in the population with schizophrenia of several nations, such as China and Japan. As the global population rise, individuals do not get complete nutrition for kids, which result in increase in occurrence of schizophrenia. Apart from this, the rise in government support for healthcare infrastructure advances further fuels the olanzapine market growth. Additionally, growth in the dysfunctional behavior among people contributes toward the expansion of the market. However, the adverse affects of the drugs used by people may hamper the market growth. The Olanzapine Market is likely to grow at a rate of 2.1% CAGR by 2027.
Olanzapine Market by Application
Bipolar Disorder
Others
Schizophrenia
Olanzapine Market by Route of Administration
Oral
Parenteral
Olanzapine Market by Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Olanzapine Market by Geography
North America
Europe
Asia Pacific
Rest of the World
On the basis of application, the market for Olanzapine is classified into Bipolar Disorder, Others and Schizophrenia. The Schizophrenia segment type is anticipated to hold the greatest share in the market. The factor which propels the growth of the segment is an increase in incidences of mental illness. For example, as per the National Institute of Mental Health (NIH) in the U.S., 52.9 million adults lived with mental illness in 2020. Therefore, a rise in incidences of mental illness, which needs olanzapine medication as a treatment to treat the disease, accelerates market growth.
Further, the market is based on Route of Administration, which is furcated into Oral and Parenteral. Compared to parenteral the oral route of administration segment is having the significant share in the market. This can be ascribed to the increased adoption of oral drugs owing to high patient compliance, noninvasive, convenient to handle, and not needing any specific sterile conditions. For example, the Sun Pharmaceutical Industries Ltd. provides oral olanzapine tablets.
Based on the market for distribution channel, the market is segmented into Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers. The Drug stores and Retail Pharmacies are projected to capture the maximum share in the market. The easy availability of olanzapine drugs in the Drug stores and Retail Pharmacies is the key reason for the segment growth.
As per the geographical analysis, the olanzapine market is segregated as North America, Europe, Asia Pacific and Rest of the World. North America has the significant share in the market. This is owing to the universal usage of the product by patients in the region and leading manufacturers creating the product in the region.
Globally, the incidence of bipolar treatment is a vital driver of the olanzapine market growth. There is no exact medication available for the olanzapine disorder. Factors such as disturbing thoughts, loss of interest in life, abnormal emotions are few of the symptoms of olanzapine. These disorders are same to depression. The more availability of bipolar treatment is fueling more demand for the global olanzapine market. Therefore, it fuels the global olanzapine market growth.
Few notable vendors of the olanzapine market are Alkermes, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, Eli Lilly and Company, apotex inc., Dr. Reddy's Laboratories Ltd., Torrent Group, Novartis AG, and Viatris
Henceforth, the schizophrenia, bipolar and other mental disorders are considered as a serious condition across the world, regardless of age, gender and other factors. There is no proper treatment for these conditions but, the olanzapine is considered to have to have significant role in controlling the symptoms of mental disorders.
The several factors are included in the study which are impacting the market growth and restricting the market.
This report consists of the segmentations and sub segmentations and the segment’s contribution to the market growth.
The report further covers the profiles of the key vendors in market coupled with their strategies such as product launches, company expansions and acquisitions.
Further, the report depicts the penetration of the market in the various regions.
Olanzapine Market by Application
Bipolar Disorder
Others
Schizophrenia
Olanzapine Market by Route of Administration
Oral
Parenteral
Olanzapine Market by Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Olanzapine Market by Geography
North America
Europe
Asia Pacific
Rest of the World
On the basis of application, the market for Olanzapine is classified into Bipolar Disorder, Others and Schizophrenia. The Schizophrenia segment type is anticipated to hold the greatest share in the market. The factor which propels the growth of the segment is an increase in incidences of mental illness. For example, as per the National Institute of Mental Health (NIH) in the U.S., 52.9 million adults lived with mental illness in 2020. Therefore, a rise in incidences of mental illness, which needs olanzapine medication as a treatment to treat the disease, accelerates market growth.
Further, the market is based on Route of Administration, which is furcated into Oral and Parenteral. Compared to parenteral the oral route of administration segment is having the significant share in the market. This can be ascribed to the increased adoption of oral drugs owing to high patient compliance, noninvasive, convenient to handle, and not needing any specific sterile conditions. For example, the Sun Pharmaceutical Industries Ltd. provides oral olanzapine tablets.
Based on the market for distribution channel, the market is segmented into Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers. The Drug stores and Retail Pharmacies are projected to capture the maximum share in the market. The easy availability of olanzapine drugs in the Drug stores and Retail Pharmacies is the key reason for the segment growth.
As per the geographical analysis, the olanzapine market is segregated as North America, Europe, Asia Pacific and Rest of the World. North America has the significant share in the market. This is owing to the universal usage of the product by patients in the region and leading manufacturers creating the product in the region.
Globally, the incidence of bipolar treatment is a vital driver of the olanzapine market growth. There is no exact medication available for the olanzapine disorder. Factors such as disturbing thoughts, loss of interest in life, abnormal emotions are few of the symptoms of olanzapine. These disorders are same to depression. The more availability of bipolar treatment is fueling more demand for the global olanzapine market. Therefore, it fuels the global olanzapine market growth.
Few notable vendors of the olanzapine market are Alkermes, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, Eli Lilly and Company, apotex inc., Dr. Reddy's Laboratories Ltd., Torrent Group, Novartis AG, and Viatris
Henceforth, the schizophrenia, bipolar and other mental disorders are considered as a serious condition across the world, regardless of age, gender and other factors. There is no proper treatment for these conditions but, the olanzapine is considered to have to have significant role in controlling the symptoms of mental disorders.
The several factors are included in the study which are impacting the market growth and restricting the market.
This report consists of the segmentations and sub segmentations and the segment’s contribution to the market growth.
The report further covers the profiles of the key vendors in market coupled with their strategies such as product launches, company expansions and acquisitions.
Further, the report depicts the penetration of the market in the various regions.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. APPLICATION: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Bipolar Disorder
5.3. Others
5.4. Schizophrenia
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug stores and Retail Pharmacies
7.4. Online Providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Alkermes, Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Sun Pharmaceutical Industries Limited
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Teva Pharmaceutical Industries Limited
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Aurobindo Pharma Ltd
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Eli Lilly and Company
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. apotex inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Dr. Reddy's Laboratories Ltd.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Torrent Group
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Novartis AG
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Viatris
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. APPLICATION: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Bipolar Disorder
5.3. Others
5.4. Schizophrenia
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Parenteral
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug stores and Retail Pharmacies
7.4. Online Providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Alkermes, Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Sun Pharmaceutical Industries Limited
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Teva Pharmaceutical Industries Limited
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Aurobindo Pharma Ltd
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Eli Lilly and Company
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. apotex inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Dr. Reddy's Laboratories Ltd.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Torrent Group
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Novartis AG
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Viatris
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL OLANZAPINE MARKET VALUE FOR BIPOLAR DISORDER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL OLANZAPINE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL OLANZAPINE MARKET VALUE FOR SCHIZOPHRENIA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL OLANZAPINE MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL OLANZAPINE MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL OLANZAPINE MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL OLANZAPINE MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL OLANZAPINE MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. U.S OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 17. U.S OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 18. U.S OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. CANADA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 20. CANADA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 21. CANADA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 22. EUROPE OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 24. EUROPE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 25. EUROPE OLANZAPINE MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 26. GERMANY OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 27. GERMANY OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. U.K OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. U.K OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 31. U.K OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. FRANCE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 33. FRANCE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 34. FRANCE OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 35. ITALY OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. ITALY OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 37. ITALY OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. SPAIN OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 39. SPAIN OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 40. SPAIN OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 41. ROE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 42. ROE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 43. ROE OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 48. CHINA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 49. CHINA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 50. CHINA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 51. INDIA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 52. INDIA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 53. INDIA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 54. JAPAN OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 55. JAPAN OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 56. JAPAN OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 63. ALKERMES, INC.: FINANCIALS
TABLE 64. ALKERMES, INC.: PRODUCTS & SERVICES
TABLE 65. ALKERMES, INC.: RECENT DEVELOPMENTS
TABLE 66. SUN PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 67. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 68. SUN PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 69. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 70. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 71. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 72. AUROBINDO PHARMA LTD: FINANCIALS
TABLE 73. AUROBINDO PHARMA LTD: PRODUCTS & SERVICES
TABLE 74. AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS
TABLE 75. ELI LILLY AND COMPANY: FINANCIALS
TABLE 76. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 77. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 78. APOTEX INC.: FINANCIALS
TABLE 79. APOTEX INC.: PRODUCTS & SERVICES
TABLE 80. APOTEX INC.: RECENT DEVELOPMENTS
TABLE 81. DR. REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 82. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 83. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 84. TORRENT GROUP: FINANCIALS
TABLE 85. TORRENT GROUP: PRODUCTS & SERVICES
TABLE 86. TORRENT GROUP: RECENT DEVELOPMENTS
TABLE 87. NOVARTIS AG: FINANCIALS
TABLE 88. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 89. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 90. VIATRIS: FINANCIALS
TABLE 91. VIATRIS: PRODUCTS & SERVICES
TABLE 92. VIATRIS: RECENT DEVELOPMENTS
TABLE 1. GLOBAL OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL OLANZAPINE MARKET VALUE FOR BIPOLAR DISORDER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL OLANZAPINE MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL OLANZAPINE MARKET VALUE FOR SCHIZOPHRENIA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL OLANZAPINE MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL OLANZAPINE MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL OLANZAPINE MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL OLANZAPINE MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL OLANZAPINE MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. U.S OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 17. U.S OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 18. U.S OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. CANADA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 20. CANADA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 21. CANADA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 22. EUROPE OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 24. EUROPE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 25. EUROPE OLANZAPINE MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 26. GERMANY OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 27. GERMANY OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. U.K OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 30. U.K OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 31. U.K OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. FRANCE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 33. FRANCE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 34. FRANCE OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 35. ITALY OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 36. ITALY OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 37. ITALY OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. SPAIN OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 39. SPAIN OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 40. SPAIN OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 41. ROE OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 42. ROE OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 43. ROE OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC OLANZAPINE MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 48. CHINA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 49. CHINA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 50. CHINA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 51. INDIA OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 52. INDIA OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 53. INDIA OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 54. JAPAN OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 55. JAPAN OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 56. JAPAN OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD OLANZAPINE MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD OLANZAPINE MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD OLANZAPINE MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 63. ALKERMES, INC.: FINANCIALS
TABLE 64. ALKERMES, INC.: PRODUCTS & SERVICES
TABLE 65. ALKERMES, INC.: RECENT DEVELOPMENTS
TABLE 66. SUN PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 67. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 68. SUN PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 69. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS
TABLE 70. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES
TABLE 71. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS
TABLE 72. AUROBINDO PHARMA LTD: FINANCIALS
TABLE 73. AUROBINDO PHARMA LTD: PRODUCTS & SERVICES
TABLE 74. AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS
TABLE 75. ELI LILLY AND COMPANY: FINANCIALS
TABLE 76. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 77. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 78. APOTEX INC.: FINANCIALS
TABLE 79. APOTEX INC.: PRODUCTS & SERVICES
TABLE 80. APOTEX INC.: RECENT DEVELOPMENTS
TABLE 81. DR. REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 82. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 83. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 84. TORRENT GROUP: FINANCIALS
TABLE 85. TORRENT GROUP: PRODUCTS & SERVICES
TABLE 86. TORRENT GROUP: RECENT DEVELOPMENTS
TABLE 87. NOVARTIS AG: FINANCIALS
TABLE 88. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 89. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 90. VIATRIS: FINANCIALS
TABLE 91. VIATRIS: PRODUCTS & SERVICES
TABLE 92. VIATRIS: RECENT DEVELOPMENTS
